Clinical Trials Browser

Phase 2 × Acrocephalosyndactylia × pemigatinib × Clear all

NCT03822117 2025-11-04

Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Phase 2 Terminated

111 enrolled 17 charts

Acrocephalosyndactylia

NCT04003610 2025-11-04

Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

Phase 2 Terminated

7 enrolled 10 charts

Acrocephalosyndactylia, Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT02872714 2025-08-14

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)

Phase 2 Completed

263 enrolled 20 charts

Acrocephalosyndactylia, Carcinoma, Transitional Cell

NCT02924376 2025-08-14

Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)

Phase 2 Completed

147 enrolled 22 charts 2 FDA

Gastrointestinal

Acrocephalosyndactylia, Cholangiocarcinoma

NCT05253807 2025-08-05

FIGHT-210

Phase 2 Completed

8 enrolled 13 charts

Acrocephalosyndactylia, Carcinoma, Non-Small-Cell Lung, Recurrence